CAPN1 and esophageal cancer: Additionally, in esophageal cancer treated by cisplatin, an identified mechanism of action involves the activation of calpain-1/2 (CAPN1/2)/Bcl-2 homologous antagonist/killer (BAK)/Bcl-2-associated X protein (BAX)/caspase-9/caspase-3/GSDME signaling axis [132].